Adaptimmune Therapeutics reported Q2 TECELRA sales of $11.1 million, with 16 patients invoiced, representing over 150% growth compared to Q1 2025. The full network of 30 Authorized Treatment Centers (ATCs) was nearing completion, and the company maintained a 100% commercial manufacturing success rate through the end of Q2.
The company confirmed the definitive agreement for the sale of TECELRA, lete-cel, afami-cel, and uza-cel cell therapies to US WorldMeds for $55 million upfront and up to $30 million in future milestone payments. This transaction, which was announced on July 28, 2025, officially closed on July 31, 2025. Following the closing, Adaptimmune repaid its debt facility with Hercules Capital.
As a direct result of the transaction with US WorldMeds and the repayment of all sums under the loan agreement, Adaptimmune stated that its cash and cash equivalents are sufficient to meet planned operating requirements through the 12 months following the filing of its Quarterly Report for Q2 2025. The company is now restructuring to maximize value from its remaining assets, including PRAME and CD70 directed T-cell therapies.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.